p53, mdm-2, bax and bcl-2 and drug resistance in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 26, Issue 5-6, 1997, Pages 435-449

  Johnston, James B ^a,b   Daeninck, Paul ^b   Verburg, Linda ^a   Lee, Kristine ^a   Williams, Gaynor ^b   Israels, Lyonel G ^a,b   Mowat, Michael R A ^a,b   Begleiter, Asher ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

bax; bcl 2; Chronic lymphocytic leukemia; Drug resistance; mdm 2; p53

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; DEXAMETHASONE; FLUDARABINE; GLYCOPROTEIN P; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ARTICLE; CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL;

EID: 0030687662     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709050881     Document Type: Article

References (48)

1. O'Brien, S., del Giglio, A. and Keating, M. (1995). Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85, 307-318.
2. Begleiter, A., Goldenberg, G. J., Anhalt, C. D., Lee, K., Mowat, M. R., Israels, L. G. and Johnston, J. B. (1991). Mechanisms of resistance to chlorambucil in CLL. Leuk. Res., 15, 1019-1027.
3. Saven, A. and Lawrence, L. D. (1994). 2-Chlorodeoxyadenosine: A newer purine analog active in the treatment of indolent lymphoid malignancies Am. J. Med., 120, 784-791.
4. Alessi-Severini, S., Gati, W. P., Belch, A. R. and Paterson, A. R. P. (1995). Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia Leukemia, 9, 1674-1679.
5. Begleiter, A., Verburg, L., Ashique, A., Lee, K., Israels, L. G., Mowat, M. R. A. and Johnston, J. B. (1995). Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia, 9, 1875-1881.
6. Carrera, C. J., Terai, T., Lotz, M., Curd, J. G., Piro, L. D., Beutler, E. and Carson, D. A. (1990). Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. J. Clin. Invest., 86, 1480-1488.
7. Robertson, L. E., Chubb, S., Meyn, R. E., Story, M., Ford, R., Hittelman, W. N. and Plunkett, W. (1993). Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood, 81, 143-150.
8. Begleiter, A., Lee, K., Israels, L. G., Mowat, M. R. A. and Johnston, J. B. (1994). Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia, 8 Suppl 1, 103-106.
9. Selivanova, G. and Wiman, K. G. (1995). p53: A cell cycle regulator activated by DNA damage. Advances in Cancer Res., 66, 143-180.
10. El Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, K. W., Kinzler, E. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
11. Waga, S., Hannon, G. J., Beach, D. and Stillman, B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578.
12. Chen, C. Y., Olmer, J. D., Zhan, Q., Fornace, A. J. Jr., Vogelstein, B. and Kastan, M. B. (1994). Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci U. S. A., 91, 2684-2688.
13. Price, B. D. and Park, S. J. (1994). DNA damage increases the levels of mdm-2 messenger RNA in wtp53 human cells. Cancer Res., 54, 896-899.
14. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Huffman, B. and Reed, J. C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9, 1799-1805.
15. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
16. Fisher, D. E. (1994). Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542.
17. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. and Jacks, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847-849.
18. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J. Jr., Magrath, I., Kohn, K. W. and O'Connor, M. (1994). p53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830.
19. Fisher, D. E., Bodis, S., Lowe, S., Takemoto, C., Housman, D., and Jacks, T. (1994). Restoration of apoptosis in p53 deficient tumor cells. Blood, 84(Suppl), 111 a.
20. El Rouby, S., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R. and Newcomb, E. W. (1993). p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
21. Dohner, H., Fischer, K., Bentz, M., Hansen, K. Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkman, M., Galle, P. R., Poustka, A., Hunstein, W. and Lichter, P. (1995). p53 gene deletion predicts for poor survival therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
22. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619.
23. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G. and Thompson, C. B., (1993). Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608.
24. Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B. and Korsmeyer, S. J. (1995). Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell, 80, 285-291.
25. Reed, J. C. (1994). Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124, 1-6.
26. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A. and Reed, J. C. (1995). Cloning and functional analysis of BAG-1. A novel Bcl-2 binding protein with anticell death activity Cell, 80, 279-284.
27. Haldar, S., Jena, N. and Croce, C. M. (1995). Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92, 4507-1511.
28. Sentman, C. L., Shutter, J. R., Hockenberry, D., Kanagawa, O. and Korsmeyer, S. J. (1991). Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888.
29. Fisher, T. C., Milner, A. E., Gregory, C. D., Jackman, A. L., Aherne, G. W., Hartley, J. A., Dive, C. and Hickman, J. A. (1993). Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res., 53, 3321-3326.
30. L can confer a multidrug resistance phenotype. Blood, 86, 1903-1910.
31. Schena, M., Larsson, L.-G., Gottardi, D., Gaidano, G., Caisson, M., Nilsson, K. and Caligaris-Cappio, F. (1992). Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood, 79, 2981-2989.
32. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. and Reed, J. C. (1993). Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood, 82, 1820-1828.
33. Watanabe, T., Hotta, T., Ichikawa, A., Kinoshita, T., Nagai, H., Uchida, T., Murate, T. and Saito, H. (1994). The mdm2 oncogene overexpression in chronic lymphocytic leukema and low-grade lymphoma of B-cell origin. Blood, 84, 3158-3165.
34. Johnston, J. B., Lee, K., Verburg, L., Blondal, J., Mowat, M. R., Israels, L. G. and Begleiter, A. (1992). Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2′-deoxycoformycin. Leuk. Res., 16, 781-788.
35. Harlow, L. and Lane, D. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press.
36. Chomczynski, P. and Sacchi, N. (1987). Single-step method of RNA isolation by acid guamdium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
37. Church, G. M. and Gilbert, W. (1984). Genomic sequencing. Proc Natl. Acad. Sci. U.S.A., 81, 1991-1995.
38. Kocialkowski, S., Pezzela, F., Morrison, H., Jones, M., Laha, S., Harris, A. L., Mason, D. Y. and Gatter, K. C. (1995). Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br. J. Haematol., 89, 55-60.
39. Kasuga, T., Cheng, J. and Mitchelson, K. R. (1995). Metastable single-strand DNA conformational polymorphism analysis results in enhanced polymorphism detection In PCR Methods and Applications, pp 277-233. Cold Spring Harbor Laboratory Press
40. Peng, H., Du, M., Ji, J., Isaacson, P. G. and Pan, L. (1995). High-resolution SSCP analysis using polyacrylamide agarose composite gel and a background-free silver staining method. Biotechniques, 19, 411-414.
41. Nakamura, H., Said, J. W., Miller, C. W. and Koeffler, H. P. (1993). Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related syndrome. Blood, 82, 920-926.
42. Resnick, J. M., Cherwitz, D. and Knapp. D. (1995). A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch. Pathol. Lab. Med., 119, 360-366.
43. Lu, X. and Lane, D. P. (1993). Differential induction of transcriptionally active p53 following U.V. or ionizing radiation: Defects in chromosome instability syndromes? Cell, 75, 765-778
44. Zhan, Q., Fan, S., Bae, I., Guillouf, C., Liebermann, D. A., O'Connor, P. M. and Fornace, A. J. (1994). Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9, 3743-3751.
45. McConkey, D. J., Chandra, J., Wright, S., Plunkett, W., McDonnell, T. J., Reed, J. C. and Keating, M. (1996). Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J. Immunol., 156, 2624-2630.
46. Thomas, A., El Rouby, S., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M. and Newcomb, E. W. (1996) Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12, 1055-1062.
47. Campos, L., Rouault, J.-P., Sabido, O., Oriol, P., Roubi, N., Vasseon, C., Archimbaud, E., Magaud, J.-P. and Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
48. Maung, Z. T., MacLean, F. R., Reid, M. M., Pearson, A. D. J., Proctor, S. J., Hamilton, P. J. and Hall, A. G. (1995). The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol., 88, 105-109.